

**November 07, 2022**

National Stock Exchange of India Limited,  
Listing Department  
Exchange Plaza, 5th Floor,  
Bandra (E), Mumbai-400051

BSE Limited  
Listing Department Corporate Relationship Department  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort, Mumbai-400001

Symbol: **ORCHIDPHARMA**

Scrip Code: **524372**

**Subject: Intimation under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir/Madam,

Notice pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, be and is hereby given that a meeting of the Board of Directors of Orchid Pharma Limited (“**the Company**”) is scheduled to be held on Monday, November 14, 2022 *inter alia*, to consider and approve Standalone & Consolidated Un-Audited Financial Results of the Company for the quarter and half year ended September 30, 2022.

In continuation to our earlier announcement intimating the Trading Window Closure period, we would like to inform you that the Trading Window for dealing in the shares of the Company is closed from October 01, 2022 and shall remain closed till 48 hours after declaration of Un-Audited Financial Results of the Company for quarter and half year ended September 30, 2022.

You are requested to take the above intimation on record.

Thanking You,  
For **Orchid Pharma Limited**

**Manish Dhanuka**  
**Managing Director**  
DIN: 00238978